Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa
Health

Agilent secures FDA nod for first-of-its-kind ovarian cancer diagnostic

Agilent Technologies (NYSE:A) announced today that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx as the first and only companion diagnostic to identify first-line patients with epithelial ovarian cancer (EOC) eligible for Merck’s blockbuster immunotherapy, KEYTRUDA.

Leia mais: Agilent secures FDA nod for first-of-its-kind ovarian cancer diagnostic